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*
                                                 
* Abbreviations. 
A-SMase, acid sphingomyelinase; BSA, bovine serum albumin; CD-95L, CD-95 ligand; 
DAG, diacylglycerol; C2-ceramide, N-acetyl-sphingosine; C6-ceramide, N-hexanoyl-
sphingosine; DAGK, diacylglycerol kinase; DCF, 2', 7'-dichlorofluorescein; DCFH, non-
fluorescent 2', 7'-dichlorofluorescein; DCFH-DA, 2', 7'-dichlorofluorescein diacetate; DMSO, 
dimethyl sulfoxide; FS, forward scatter; GSH, glutathione; GSSG, oxidised glutathione; 
MdX, median X; NAC, N-acetyl cysteine; N-SMase, neutral sphingomyelinase; PBL, 
peripheral blood lymphocyte; PBMNC, peripheral blood mononuclear cells; PBS, phosphate 
buffered saline; PHA, phytohemagglutinin; PI, propidium iodide; ROS, reactive oxygen 
species; SMase, sphingomyelinase; SOD, superoxide dismutase; SS, side scatter; TLC, thin 
layer chromatography; TNFα, tumour necrosis factor alpha; [peroxide]cyt, cytosolic peroxide; 
[peroxide]m, mitochondrial peroxide; ∆DCF, change in DCF. 
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Synopsis. 
 
Ceramide (a sphingolipid) and reactive oxygen species (ROS) are each partly responsible for 
intracellular signal transduction in response to a variety of agents.  It has been reported that 
ceramide and ROS are intimately linked, and show reciprocal regulation.  Utilising synthetic, 
short chain ceramide to mimic the cellular responses to fluctuations in natural endogenous 
ceramide formation, or stimulation of CD95 to induce ceramide formation, we describe that 
the principal redox altering property of ceramide is to lower the cytosolic peroxide 
concentration.  Apoptosis of Jurkat T-cells, primary resting and PHA activated human 
peripheral blood T lymphocytes was preceded by loss in cytosolic peroxide ([peroxide]cyt), 
measured by the peroxide sensitive probe DCFH-DA (also reflected in a lower rate of SOD 
inhibitable cytochrome c reduction), and this was not associated with loss of membrane 
integrity.  Where growth arrest of U937 monocytes was observed with no loss of membrane 
integrity, the reduction in cytosolic peroxide was of a lower magnitude than that preceding 
the onset of apoptosis in T-cells.  Furthermore, reducing the cytosolic peroxide level in U937 
monocytes prior to the application of synthetic ceramide by pre-treatment with either of the 
anti-oxidants N-acetyl cysteine (NAC) or glutathione (GSH) conferred apoptosis.  However, 
NAC or GSH did not affect the kinetics or magnitude of ceramide induced Jurkat T-cell 
apoptosis.   Therefore, the primary redox effect of cellular ceramide accumulation is to lower 
the [peroxide]cyt of both primary and immortalised cells, the magnitude of which dictates the 
cellular response.   
Keywords:  apoptosis, growth arrest, CD95, reactive oxygen species, redox 
compartmentalisation. 
 3 
Phillips & Griffiths,  Ceramide reduces cytosolic peroxide. 
Introduction. 
The sphingolipid ceramide has been identified as an important, but not exclusive, 
signalling intermediate in the induction of cellular responses to a variety of agents.  These 
include both physiological, e.g. TNFα [1-4], interleukin-1β [IL-1β; 5], CD-95 (APO-1/Fas; 
1,6-8] and toxicological, e.g. hydrogen peroxide (H2O2), heat shock, UV light, ionising 
radiation [4, 9], anticancer drugs [10-12] or the bacterial endotoxin LPS [13].  Ceramide 
accumulation in response to extracellular agents appears to be driven either by the action of 
sphingomyelinases (SMase), catalysing the hydrolysis of sphingomyelin to ceramide [2, 6, 9], 
or through de novo ceramide generation via ceramide synthase [10-11].  Downstream events, 
which vary according to cell type and stimulus, include apoptosis and proliferation, following 
activation of intracellular signalling cascades. 
The application of cell permeable, synthetic ceramides or bacterial sphingomyelinase 
to a variety of cell types is able to induce the apoptotic [2, 4, 12] and proliferative [14] 
responses supporting a cell type specific signalling role.  Cell cycle arrest by 
dephosphorylation of the retinoblastoma gene product [13,15,16], differentiation [17], and 
senescence [18] have also been observed upon cell treatment with synthetic ceramide. 
Endogenous cellular ceramide and ROS levels are elevated in response to overlapping 
external stimuli, and the external application of synthetic ceramides or the ROS, H2O2, 
induces the activation of common downstream protein targets. Therefore, evidence suggests 
that the effects of ROS and ceramide are intimately related.  Indeed, recent observations are 
suggestive of an association between ROS and ceramide at two levels; firstly, in regulation of 
ceramide metabolism where the intracellular antioxidant negatively regulates the activity of 
neutral sphingomylinase (N-SMase) but not acid sphingomyelinase [A-SMase; 2, 19, 20], and 
secondly as a putative mediator of ceramide signalling following disruption of the 
mitochondrial electron transport chain [21-24].  
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However, the effects of antioxidants in detoxifying ceramide-induced apoptosis are 
inconsistent.  U937 monocytes or MCF-7 breast carcinoma cell lines are not protected from 
short chain ceramide induced cell death by pre-treatment with the antioxidants GSH and 
NAC [2, 25] whereas catalase was reported to antagonise the lethality of C2-ceramide in 
WEHI 231 B cells [26].  Additionally, in U937 monocytes, C2-ceramide did not lead to the 
predicted enhancement of fluorescence by the cytosolic peroxide sensitive dye DCF [25].   
We have previously described that the cellular responses of apoptosis or growth arrest 
induced by synthetic ceramides are associated with the degree of magnitude of  [peroxide]m 
formation and the associated alteration in redox state [23].  However, we also observed that 
BSO-mediated GSH depletion in monocytes and T cells protected against ceramide induced 
changes in cell cycle, indicating that complex compartmental differences in levels of 
oxidants/antioxidants may govern outcome. Furthermore, given the relatively small 
perturbation in [peroxide]m observed we questioned whether these changes are capable of 
promoting extra-mitochondrial signalling.  Consequently, we have investigated the effects of 
ceramide, and its generation by the physiological CD95 ligand (CD95L), on the cytosolic 
peroxide concentration ([peroxide]cyt) in the context of the ensuing cellular response.  Herein, 
we describe that the primary redox effect of cellular ceramide accumulation is to lower the 
[peroxide]cyt of both primary and immortalised cells, the magnitude of which dictates the 
cellular response.   
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Experimental 
Materials. 
All reagents were obtained from Sigma Chemical Company (Poole, UK), solvents 
were from Fisher (Loughborough, UK) and all gases from BOC Ltd (Guildford, UK) unless 
otherwise stated.  RPMI 1640, foetal bovine serum and penicillin (1000U/ml)/streptomycin 
(10,000µg/ml; P/S) were purchased from GibcoBRL (Paisley, UK).  Human monoclonal anti-
human CD95 (Fas/APO-1) antibody was from R&D Systems (Abingdon, UK).  C2-ceramide 
(N-acetyl-sphingosine) and C6-ceramide (N-hexanoyl-sphingosine), were obtained from 
Biomol Research Laboratories (Plymouth Meeting, PA, USA).  Escherichia coli 
diacylglycerol kinase (DAGK) and n-octyl-β-D-glycopyranoside were purchased from 
Calbiochem (Nottingham, UK).  [γ32P] ATP was purchased from Amersham Life Science 
Ltd. (Little Charford, UK).  Fluorescently tagged monoclonal antibodies (MoAb) and isotype 
negative controls were obtained from Diaclone, (Besançon Cedex, France) or Serotec Ltd 
(Kidlington, UK). 
 2’, 7’,-dichlorofluorescein diacetate (DCFH-DA) was dissolved in dimethyl sulfoxide 
(DMSO) to stock solutions of 75mM.  Subsequent dilutions were made with serum free 
RPMI 1640.  The antioxidants N-acetylcysteine (NAC) and glutathione (GSH) were made up 
in serum free RPMI 1640.  In the [peroxide]cyt assays, the final cellular concentration of 
DMSO employed did not exceed 0.1%.  Monoclonal anti-human CD95 (Fas/APO-1) 
antibody was reconstituted in sterile phosphate buffered saline (PBS; 0.01M Na2HPO4, 
0.002M KH2PO4, 0.003M KCl, 0.137M NaCl; pH 7.4) containing 0.1% fraction V bovine 
serum albumin to a concentration of 500µg/ml with further dilutions being made in 
PBS/0.1% BSA.  C2-/C6-ceramide were dissolved in anhydrous DMSO to a stock solution of 
20mM.  Subsequent dilutions were made in 1mM fatty acid free BSA in PBS.   
 
 6 
Phillips & Griffiths,  Ceramide reduces cytosolic peroxide. 
Methods 
Cell culture and stimulation. 
The acute human T-cell leukaemia cell line, Jurkat, and the human monocyte cell line, 
U937, were maintained in RPMI 1640 media, supplemented with 10% heat inactivated foetal 
calf serum and 1% penicillin/streptomycin.  Cells were incubated at 37oC in a humidified 
atmosphere of 5% CO2 and 95% air.  The number of viable cells per ml was determined by 
trypan blue exclusion using an improved Neubauer haemocytometer (Weber Scientific 
International Ltd., Teddington, UK).  Cells at a concentration of 2x106/ml were serum starved 
for 4 hours in the described incubator conditions prior to treatment.  Where indicated, cells 
were treated with CD95L or C2-/C6-ceramide for the times and concentrations noted, 
incubations at 37oC in a humidified 5% CO2/95% air incubator.  To investigate the role of 
reactive oxygen species (ROS) in the cellular responses to the above agents, cell suspensions 
were pre-treated for 4 hours with 10mM NAC or GSH.  The role of surface gamma glutamyl 
transpeptidase activity in providing the GSH-mediated antioxidant protection was 
investigated through pre-incubation of cells with 1mM acivicin for 30 minutes prior to GSH 
exposure. To prevent the cellular export of glutathione disulphide (GSSG), cells were pre-
treated for 1 hour with L-methionine or L-cystathionine [34].  Further inhibitory experiments 
with the NADPH oxidase inhibitor, diphenylene iodinium (2.5µM), were established in order 
to elucidate any role of this enzyme in modulation of intracellular redox. Stimulation was 
discontinued by removing cells suspensions from culture vessels, centrifuging at 1000xg 
(Eppendorf centrifuge 5415D, Hamburg, Germany) for 5 minutes and washing twice with 
1ml of ice cold PBS prior to further experimental manipulation. 
Individual additions to cells suspensions did not exceed 1% of the total volume and 
were dispersed with gentle mixing by pipette.  Control experiments were conducted under 
identical conditions as tests, employing vehicle treatment. 
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T-cell isolation and cell culture. 
Briefly, 40mls of venous blood was obtained from consenting adults into 10% sodium 
citrate (4% w/v) to prevent coagulation.  Further manipulation of the blood was conducted 
under aseptic conditions.  Blood was diluted with PBS containing 0.1% BSA (w/v) in the 
ratio 2:5 into 50ml conical tubes (Orange Scientific, Braine-l’Alleud, Belgium).  Peripheral 
blood mononuclear cells (PBMNC) were isolated by density gradient centrifugation over 
LymphoprepTM (Nycomed Pharma AS, Oslo, Norway) and the resting T-cells purified by 
negative isolation employing magnetic beads (Dynal A.S., Oslo, Norway).  For ex vivo 
examination, T-cells were analysed for [peroxide]cyt and lipid content immediately following 
isolation.  Additionally, resting T-cells were cultured for 72 hours in RMPI 1640 
supplemented with 10% FCS and 1% penicillin/streptomycin (P/S) with or without 10µg of 
phytohemagglutinin (PHA) per 2x106 /ml T-cells to elicit activation.  Isolated T-cells were 
incubated at 37oC in a humidified atmosphere of 5% CO2 and 95% air.  Prior to further 
experimental manipulation, T-cells in culture were washed twice, resuspended in serum free 
RPMI 1640 and treated as described for immortalised cell lines   
Phenotypic analysis of peripheral blood lymphocytes by immunofluorescence. 
 The percentage of CD3+ peripheral blood T-lymphocytes (PBL) and their percentage 
activation (determined as the appearance of CD25 (IL-2α receptor) was evaluated by flow 
cytometry following negative isolation from blood.  The purity of extracted PBL was 
assessed by the percentage of CD3+ PBL and monocyte contamination evaluated by the 
presence of CD14+ cells within the whole sample.  PBS washed PBL ex vivo or following 72 
hour culture were treated with 10µl of antibody per 106 cells and incubated on ice in the dark 
for 30 minutes. The antibodies used were the mouse monoclonal anti-human CD3 antigen 
(PE conjugated),  mouse monoclonal anti-human CD25 antigen (FITC conjugated) and 
mouse monoclonal anti-human CD14 antigen (RPE-Cy5 conjugated).  For each sample, 
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isotype negative controls of the MoAb were used to establish background fluorescence.  PBL 
were fixed in 250µl of 4% formaldehyde solution.  Samples were then vortexed vigorously 
and incubated in the dark for a further 15 minutes followed by the addition of 200µl of Isoton 
(Beckman Coulter, Miami, FL, USA).  Samples were again vortexed and incubated in the 
dark, at room temperature for a minimum of 10 minutes.  Samples were stored in the dark at 
4oC for up to 24 hours prior to analysis without significantly affecting results.  Samples were 
then analysed by flow cytometry (EPICS XL-MCL, Beckman Coulter) utilising 3-way 
colour compensation and corrected for background fluorescence detected with isotype 
negative controls.  A minimum of 10,000 PBL were analysed per sample using the following 
gating strategy:  The percentage activation of CD3+ PBL was evaluated on a dual parameter 
histogram of log FL2 (CD3 PE) versus log FL1 (CD25 FITC).  The purity of PBL extracted 
was assessed as the percentage of CD3+ cells on an ungated histogram of side scatter (SS) 
versus log FL2 (CD3 PE).  Monocyte contamination was determined on an ungated 
histogram of log FL4 (CD14 PE-Cy5) versus count. 
Flow cytometric DNA cell cycle analysis. 
Briefly, PBS washed cells were centrifuged at 100xg (Eppendorf centrifuge 5415D, 
Hamburg, Germany) for 5 minutes, the supernatant removed and the resulting cell pellet 
resuspended in 1ml hypotonic fluorochrome solution (50µg/ml PI in 0.1% sodium citrate and 
0.1% Triton x-100) to extract and stain nucleoids [27].  Samples were incubated in the dark at 
4oC for 14-24 hours prior to flow cytometric cell cycle analysis.  Propidium iodide (PI) 
fluorescence of individual nuclei was measured using an EPICS XL-MCL flow cytometer 
(Beckman-Coulter) equipped with a 488nm air-cooled Argon laser.  Forward scatter (FS) and 
SS of the nuclei were simultaneously measured in addition to linear and log red fluorescence 
(FL3, bandwidth 605nm-635nm).  Clumps of nuclei were eliminated by appropriate gating.  
For each analysis, 20,000 events were recorded on the gated FL3 detector.  The percentage of 
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actual apoptosis was determined by quantifying the number of hypoploid (subdiploid) nuclei.  
Values were also expressed as a percentage of specific apoptosis according to the formula 
specific apoptosis = (T-C)/(100-C) x100, where T equals the percentage of apoptotic events 
from treated cells, and C equals the percentage of apoptotic events from control cells.  The 
percentage of nuclei in the G0/G1 phase of the cell cycle was quantified using Multi-Cycle 
for Windows (Phoenix Flow Systems, San Diego, U.S.A.). 
Evaluation of cytosolic peroxide levels. 
A procedure adapted from Bass et al., [28] was used to measure cytosolic peroxide 
levels ([peroxide]cyt) cells by flow cytometry as the fluorescence generated from cells loaded 
with the peroxide sensitive fluorescent probe DCFH-DA.  DCFH-DA rapidly diffuses into 
the cytosol of cells where it is hydrolysed to the non-fluorescent, oxidation sensitive DCFH.  
In the presence of [peroxide]cyt, DCFH is rapidly oxidised to the non-diffusible, fluorescent 
DCF.  Cells were loaded with 50µM DCFH-DA per 2x106 cells for the final 40 minutes of 
exposure to varying concentrations and incubation periods with CD95 or ceramide.  
Immediately following agent/DCFDA incubation, cells were analysed by flow cytometry 
(EPICS XL-MCL), with the first control population always adjusted to the third log decade, 
giving a MdX value of ~100. Measurements of FS, side SS and log FL1 fluorescence (green 
light, band width 505nm-545nm were recorded.  The viable cell population, determined by 
FS and SS properties, were gated to exclude debris, clumped cells or machine noise.  10,000 
cells were examined from each sample on a histogram of log FL1 (DCF fluorescence) versus 
count. In control experiments, DCF was seen to have no quenching effect on hydrogen 
peroxide induced DCF fluorescence. 
Evaluation of SOD-inhibitable cytochrome c reduction. 
Cells (200µl of 107/ml) in HBSS, were dispensed into a optically clear flat bottomed 
96 well plate containing 160µM cytochrome c, in the presence or absence of C2- ceramide 
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(20µM) and either superoxide dismutase (3000U/ml) or diphenylene iodinium (2.5µM). 
Cytochrome c reduction was monitored at 550nm following incubation with the 
aforementioned agents at 37oC for 1 hour or 16 hours.  Superoxide release was calculated in 
nmols/107 cells using the molar extinction coefficient for cytochrome c as 21 x 103 M-1cm-1 at 
an 550nm. 
Analysis of [peroxide]cyt levels of mononuclear cells from peripheral whole blood. 
Blood (200µl) was treated with C2-/C6-ceramide, for 1 hour in a water bath in the dark 
at 37oC with gentle horizontal shaking.  Optimal concentrations were pre-determined from 
the responses achieved from cell lines in vitro.  At Tend –20 minutes, DCFH-DA was added to 
give a final concentration of 50µM, and samples returned to the water bath.  At the end of 
agent treatment period, blood was stained with antibodies at a saturating concentration of at 
least 10µl of antibody per 100µl of blood.  Samples were then incubated on ice for a further 
30 minutes.  To identify monocytes and T-cells, PBL were stained with mouse monoclonal 
anti-human CD3 antigen PE conjugated and mouse monoclonal anti-human CD14 RPE-Cy5 
conjugated respectively.  3-way colour compensation to account for overlapping emission 
spectra of the fluorescent-tagged antibodies and DCF was applied.  Red blood cells were 
lysed and the mononuclear cell (MNC) population fixed with Optilyse C (Beckman Coulter), 
as described above. Cell suspensions were immediately analysed by flow cytometry.  
Histograms of log FL2 (CD3 PE) versus SS and log FL4 (CD14 RPE-Cy5) versus SS were 
used to gate CD3+ lymphocytes and CD14+ monocytes respectively.  The DCF fluorescence 
of CD3+ T-lymphocytes and CD14+ monocytes were analysed on separate single parameter 
histograms of log integral FL1 (DCF) versus count.  The median fluorescence (MdX) 
intensity of each sample was recorded.   
Determination of intracellular glutathione content 
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This was done according to the recycling assay of Tietze, [29].  Briefly, at the end of 
each treatment period, samples were washed with ice cold PBS by centrifugation at 2,300rpm 
for 5 minutes.  An aliquot was removed for protein determination and then cells were 
resuspended in 3.33% 5-sulfosalicyclic acid dihydrate, vortexed vigorously and centrifuged at 
13,000rpm to precipitate interfering proteins. Supernatant (25µl) was added to 50µl 5,5'-
Dithio-bis (2-Nitrobenzoic acid; DTNB; 6mM), and 150ul NADPH (0.3mg/ml) in triplicate, 
and incubated at 37oC for 3 minutes, prior to addition of 25µl glutathione reductase (GSR; 
20U/ml).  The plate was immediately read at 420nm and then read again at +1 and +5 
minutes to determine DTNB reduction.  Test sample values were calibrated against a standard 
curve of glutathione from 0-60nmoles, and expressed per mg of cellular protein. 
Protein Determination 
Protein concentration was determined in quadruplicate using the BCA assay based on 
the method of Smith et al., [30], using bovine serum albumin (BSA) as standards to calculate 
unknowns. 
Quantification of endogenous T-cell ceramide content.  
Lipids were extracted from Jurkat T-cells (2x106/ml) according to the method of 
Bligh & Dyer, [31] and the concentration of ceramide quantified by the DAGK assay as 
described [32, 33].  The mass of ceramide and DAG extracted from each cell sample was 
obtained from the standard curve constructed from known concentrations of type III ceramide 
(from bovine brain; Sigma, Poole, UK) and standardised as the lipid concentration per 106 
cells.  The efficiency of the assay was evaluated from the standard curve and a known 
concentration of C6-ceramide.  Cellular ceramide levels were adjusted according to the % 
efficiency of conversion and were always greater than 90%. 
Statistical analysis. 
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Statistical analysis was performed by one-way ANOVA followed by Tukey's or 
Dunnet’s post hoc test analysis, or Students t-test.  A p<0.05, p<0.01 or p<0.001 was 
considered to be significant. 
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Results. 
As previously reported [23], the treatment of Jurkat T-cells with 20µM C2-/C6-ceramide 
induced a rapid, time dependent elevation in the percentage of specific apoptosis which was 
significant at 3hours, but was not observed at the lower synthetic ceramide concentration of 
1-10µM (see Figure 1a).  Maximal specific apoptosis (55%) was observed following 8hrs 
treatment with 20µM C2-ceramide.  Treatment of Jurkat T-cells for longer periods of up to 36 
hours with 20µM C2 -ceramide did not further increase the percentage of specific apoptosis 
(p>0.05; see Figure 1a).  Comparable kinetics of apoptosis in Jurkat T-cells were observed 
with 0-20µM C6-ceramide (data not shown) [23]. 
During the first 16 hours of Jurkat T-cell exposure to C2-ceramide, [peroxide]cyt was 
monitored by flow cytometry using the fluorescence emission of DCF from cells pre-loaded 
with the peroxide sensitive dye DCFH-DA.  The median fluorescence (MdX) of the DCFH-
DA treated viable cell population, determined by FS and SS properties, decreased with 
immediately following exposure to 20µM C2-ceramide.  The first significant decreases in 
DCF MdX were observed at 15 minutes exposure to 20µM C2-ceramide (p<0.05) when 
compared to vehicle treated control Jurkat T cells.  Basal peroxide levels were fixed to 
~MdX=100, where a maximum decrease in ∆DCF MdX of approximately -60 arbitrary units 
(a.u) was observed at 4 hours treatment with 20µM C2-ceramide (see Figure 1b).  DCF 
fluorescence of cells exposed to 20µM C2-ceramide for greater than 8 hours was not 
measured as no further alteration in specific apoptosis were observed at these longer 
incubation periods.  ∆DCF MdX induced by 16 hours treatment of Jurkat T cells with 10µM 
C2-ceramide fell significantly to approximately -35 a.u (p<0.01) (see Figure 1b) without the 
appearance of apoptosis (p>0.05; see Figures 1a & b).  Similar alterations in ∆DCF MdX of 
Jurkat T-cells treated with 20µM C2-ceramide were observed after 45 minutes (see Figure 1b) 
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and this was not associated with the appearance of apoptosis at this time point (p>0.05; see 
Figures 1a).  Similar effects on the DCF fluorescence were observed in Jurkat T-cells 
following treatment with 0-20µM C6-ceramide (data not shown). 
As previously reported by us [23] treatment of the human monocytic cell line U937 
with either C2- or C6-ceramide (0-20µM) for up to 36 hours induced an enhancement in the 
percentage of nuclei in the G0/G1 phase of the cell cycle when compared to vehicle treated 
controls, first evident following 16 hrs treatment of U937 cells with 20µM C2-/C6-ceramide 
(p<0.05; data not shown). This was also observed at longer incubation periods with 10µM C6 
ceramide (p<0.05; see Figure 2a).  The elevation in U937 monocyte nucleoids in the G0/G1 
phase of the cell cycle was associated with the prevention of apoptosis induced by serum 
withdrawal.  Low dose C6-ceramide (1µM) exposure for 36 hours did not significantly affect 
either the percentage of nucleoids in the G0/G1 phase of the cell cycle (p>0.05) nor the 
percentage of actual apoptosis compared to that observed in vehicle treated control U937 
monocytes (p>0.05; see Figure 2a).  Monocytes treated with either 10 or 20µM C6-ceramide 
for 36 hours showed significantly elevated G0/G1 DNA content compared to vehicle controls 
(p<0.01).  At 36 hours, the G0/G1 content remained elevated to of the same extent as U937 
monocytes treated with 10 or 20µM C6-ceramide for 24 hours (data not shown; p<0.05).  
Correspondingly, the synthetic ceramide treatment of U937 monocytes induced a dose 
dependent inhibition of serum deprivation induced actual apoptosis.  C6-ceramide (10µM) 
treatment for 36 hours significantly inhibited the appearance of actual apoptosis due to serum 
starvation by approximately 12% (p<0.05).  Greater protection against actual apoptosis by 
18% (p<0.01) was seen following 20µM C6-ceramide (see Figure 2a).  Identical results were 
obtained following treatment of U937 monocytes with C2-ceramide (Data not shown). 
In U937 cells, no alteration in the intracellular H2O2 concentration (as DCF 
fluorescence) was observed for the first 30 minutes of 20µM C6-ceramide exposure when 
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compared to vehicle treated control cells (see Figure 2b).  ∆DCF MdX then rapidly decreased 
to a minimum of -40 in C6-ceramide treated U937 cells respectively within 4hrs, which then 
rose to -25 a.u. on increasing the treatment period to 8 hours (see Figure 2b).  ∆DCF MdX 
remained at –25 a.u at 16 hours incubation with 20µM C6-ceramide.  At a lower 
concentration (10µM), C6-ceramide decreased DCF fluorescence compared to control with 
slower kinetics than that observed with the higher dose (20µM), and with less potency at all  
time points examined (2, 4 and 16 hours, p<0.05; see Figure 2b).  The maximal decreases in 
∆DCF MdX of U937 cells monocytes treated with 20µM ceramide were significantly less 
than those achieved in Jurkat T-cells (p<0.01;  Figures 1b &2 b). 
Flow cytometric evaluation of the cellular uptake of the membrane impermeable dye 
PI and cell size revealed no evidence of necrosis in U937 monocytes treated with C2-/C6-
ceramide (0-20µM) for up to 16 hours.  This was confirmed in Jurkat T-cells treated with 0-
10µM C2-/C6-ceramide for 16 hours and 20µM C2-/C6-ceramide for up to 8 hours.  However, 
following 16 hours treatment of Jurkat T-cells with 20µM C2-/C6-ceramide, a subpopulation 
of Jurkat T-cells possessed reduced cell size with high PI uptake indicating late apoptosis or 
secondary necrosis (data not shown).  To confirm the specificity of effect on DCF 
fluorescence, ceramide metabolite, sphingosine-1-phosphate (S1P), was also examined. S1P 
had no effect on DCF fluorescence (data not shown). 
In order to establish the contribution of NADPH oxidase activity to any change in 
[peroxide]cyt that was measured as ∆DCF MdX, we treated cells with the NADPH oxidase 
inhibitor diphenylene iodinium (DPI), and analysed for ceramide induced changes in DCF 
fluorescence and apoptosis.  After one hour, DPI alone or in combination with 20µM C2-
ceramide did not significantly alter the DCF fluorescence observed in either Jurkat T-cells or 
U937 monocytes exposed to 20µM C2-ceramide alone (data not shown).  By 16 hours, DPI 
significantly reduced DCF MdX in U937 cells, with a trend to further reduction when co-
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incubated with ceramide (see Figure 3a).  Indeed examination of the effects of DPI on 
apoptosis showed that while inducing slight apoptosis on its own (7.8+0.9%), co-incubation 
with C2-ceramide significantly enhanced apoptosis in U937 cells to 18.6+2.3% (p<0.001) 
compared with C2-ceramide alone (see Figure 3c).  In addition, DPI significantly promoted 
C2-ceramide-induced apoptosis in Jurkat T cells (p<0.001; see Figure 3d).  Figure 3b shows 
that this was associated with a significant reduction in DCF MdX (16 hours: ceramide alone 
= 72a.u., ceramide + DPI = 25.7 a.u.; p<0.001). 
As an alteration in DCF fluorescence may be a representation of changing availability 
of catalyst or hydrolysis of DCFH-DA in ceramide treated cells, we examined whether 
ceramide could modulate cellular superoxide anion production using a specific cytochrome c 
reduction method.  Figure 3f confirms that ceramide inhibits basal superoxide production by 
Jurkat T cells after 16 hours treatment (p<0.05).  DPI in itself and in combination with C2-
ceramide was able to reduce superoxide production further in Jurkat T-cells.  Similarly, 
Figure 3e illustrates that ceramide significantly reduced superoxide production by U937 
monocytes, but that this was not further enhanced by coincubation with DPI.  As a positive 
control, the application of exogenous SOD to either U937 monocytes or Jurkat T-cells 
resulted in total loss of cytochrome c reduction demonstrating absolute dependence on 
superoxide for the reaction (see Figures 3e & f). 
 To determine the importance of  [peroxide]cyt on outcome, U937 monocytes were 
pretreated with either of the anti-oxidants NAC or GSH. Cellular GSH rose by 28% and 21% 
respectively from a basal level of 34.8nmol per mg of protein after pre-treatment with GSH 
and NAC respectively, where acivicin pretreatment significantly inhibited the elevation 
induced by exogenous glutathione (p<0.01). The antioxidants significantly prevented the 
accumulation of nucleoids in the G0/G1 phase of the cell cycle mediated by 16 hours 
exposure to 20µM C6-ceramide (p<0.01) and was accompanied by the appearance of sub-
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diploid DNA.  C6-ceramide (20µM) significantly increased the appearance of sub-diploid 
DNA of U937 monocytes pre-treated with either NAC or GSH compared to no pre-treatment 
(p<0.05). The percentage nucleoids in the G0/G1 phase of vehicle treated controls were not 
affected by pre-treatment with NAC (p>0.05) or GSH (p>0.05; see Figure 4b).  Further, there 
was no significant difference in either the inhibitory effects of NAC or GSH on synthetic 
ceramide mediated G0/G1 nucleoid accumulation (p>0.05; see Figure 4b) or the percentage 
of actual apoptosis induced by either species in the presence of either anti-oxidant (p>0.05; 
see Figure 4a).  Pre-treatment of U937 monocytes with the anti-oxidants GSH or NAC 
significantly reduced ∆DCF to approximately –35a.u (p<0.001) after 16 hours vehicle 
treatment.  On addition of 20µM C6-ceramide to NAC or GSH pre-treated U937 monocytes, 
∆DCF decreased further to approximately –55a.u, and was significantly lower than U937 
cells pre-treated with NAC or GSH alone (p<0.01; see Figure 4c).  The pre-treatment of 
Jurkat T-cells with either of the antioxidants NAC or GSH did not increase the kinetics or the 
magnitude of apoptosis induced by 20µM C2-ceramide (see Figure 5a).  Treatment of U937 
monocytes or Jurkat T-cells with  concentrations of either NAC of GSH in excess of 10µM 
were in themselves cytotoxic (data not shown).  Previously we have reported that efflux of 
oxidised GSH from the cell precedes synthetic ceramide mediated Jurkat T-cell apoptosis and 
may be a contributory mechanism to apoptosis process [23], however, pre-treatment with the 
GSH efflux inhibitors L-cystathionine or L-methionine [34] did not affect Jurkat T-cell 
apoptosis (0-20µM; p>0.05 for each concentration and species; see Figure 5b) or  G0/G1 
growth arrest in U937 monocytes (Data not shown) induced by C2-/C6-ceramide, despite 
protecting cellular glutathione status (U937 cells= 29.83+1.27nmol GSH/mg protein; U937 + 
20uM ceramide for 1hour = 25.95+1.61nmolGSH/mg protein; U937 + methionine + 20uM 
ceramide for 1 hour = 28.7+1.7 nmolGSH/mg protein, n=9).   
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To determine whether the effects observed in immortalised cells were reproduced in a 
mixed population of primary cells, T-lymphocytes and monocytes (identified by expression 
of the antigens CD3 and CD14 respectively) from peripheral whole blood were individually 
gated and the DCF fluorescence of CD3+ and CD14+ populations analysed on a single 
parameter histogram of FL1 versus count (see Figures 6a & b).  The DCF fluorescence of 
CD3+ T-cells and CD14+ monocytes displayed reduced [peroxide]cyt following the treatment 
of whole blood with 20µM C6-ceramide when compared to vehicle treated whole blood T-
cells or monocytes (see Figures 6c & d).   
To further substantiate the observations of reduced [peroxide]cyt in response to short 
chain ceramides obtained in immortalised cell lines and whole blood, primary, resting T-cells 
were extracted from venous whole blood.  Purity (as the percentage of CD3+ T-cells) was 
always greater than 94%.  Monocytic contamination was quantified simultaneously (CD14 
expression) and was always less than 1.5% (data not shown).  T-cells were then cultured in 
RPMI 1640 in the presence or absence of 10µg/ml of PHA to induce activation.  T-cell 
activation was assessed as the percentage of CD3+CD25+ T-cells.  Flow cytometry 
histograms of SS versus FS showed an increase in size of T-cells which was coupled with a 
significant elevation in CD3+CD25+ levels to 43.62 ± 15.39% positive T-cells (mean ± s.d; 
n=12) upon activation with PHA for 3 days compared to 2.605 ± 2.082% for resting T-cells 
(mean ± s.d; n=12; p<0.001).   
DNA cell cycle analysis of PHA activated T-cells revealed the appearance of S-phase 
and G2M phase nucleoids.  As expected, resting T-cells possessed no evidence of DNA in the 
S-phase or G2M phase of the cell cycle (data not shown).  A limiting factor in performing the 
necessary experiments was the number of T-cells obtained from 40mls of blood, typically 
10x106, and consequently for experimental purposes half the concentration of cells, 1x106/ml, 
was used.  Following 6 hours treatment with 0-20µM C2-ceramide, DNA cell cycle analysis 
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by flow cytometry revealed no significant accumulation of sub-diploid DNA in either resting 
(p>0.05; see Figure 7a) or activated (p>0.05) primary T-cells (see Figure 8a-d).  Furthermore, 
at this time point C2-ceramide induced a concentration dependent decrease in DCF 
fluorescence in both resting and activated T-cells (see Figures 7c & 8e) which was initially 
significant at a concentration of 5µM C2-ceramide in both cell types (p<0.05).  Following 24 
hours treatment of resting or activated T-cells with 5µM C2-ceramide DCF fluorescence was 
significantly reduced to approximately -10 a.u from vehicle treated controls (p<0.05; data not 
shown) with no significant evidence of sub-diploid DNA (p>0.05) at this time point (see 
Figures 7b & 8g).  On extending the incubation to 24 hours, C2-ceramide induced a dose 
dependent increase in the appearance of sub-diploid DNA in resting T-cells, which was first 
significant at a concentration of 10µM inducing approximately 30% DNA fragmentation 
(p<0.05) and at 20µM C2-ceramide 32% (p<0.01; see Figure 7b).  Likewise, in activated T-
cells, at 24 hours post-treatment, the extent of DNA fragmentation was identical to that 
observed in resting T-cells for each concentration of C2-ceramide (p>0.05 for each dose; see 
Figure 8f-i).   
Treatment of Jurkat T-cells with CD95L induced a time and dose dependent elevation 
in apoptosis.  Specific apoptosis was initially observed after 4 hours exposure to 1µg/ml 
(p<0.05) and 5µg/ml (p<0.05) of CD95L.  These concentrations of CD95L mediated 
maximal elevation in the percentage of specific apoptosis of approximately 70% after 12 
(p<0.01) and 16 hours (p<0.01) respectively, after which a plateau was observed.  
Incubations of Jurkat T-cells with these concentrations of CD95L did not induce further 
alterations in the percentage of specific apoptosis following 16 hours treatment (p>0.05).  
There was no significant difference in the maximal percentage specific apoptosis induced by 
1µg/ml and 5µg/ml CD95L (p>0.05).  Treatment of Jurkat T-cells with 100ng/ml of CD95L 
failed to induce any significant elevation in the percentage of specific apoptosis (p<0.05) for 
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up to 16 hours.  Intermediate concentrations of CD95L (250ng/ml and 500ng/ml) also 
induced significant time dependent elevations in the specific apoptosis, which were maximal 
after 16 hours (20%) and 36 hours (55%) respectively and significantly different to the 
maximal apoptotic response of 70% induced by higher concentrations of CD95L (p<0.001; 
see Figure 9a).   
CD95L induced a transient elevation in endogenous ceramide ([ceramide]i) levels in a 
concentration dependent fashion.  [ceramide]i increased significantly to approximately 150% 
(p<0.05) and 180% (p<0.05) of control levels following 30 minutes treatment with 0.5 and 
1µg/ml CD95L.  On increasing the incubation period to 1 hour, [ceramide]i was elevated 
further to approximately 240% (p<0.05) and 320% of control (p<0.01) by 0.5 and 1µg/ml 
CD95L respectively.  After 4 hours exposure to either 0.5 or 1µg/ml CD95L [ceramide]i 
returned to that of control levels (p>0.05 for both concentrations; see Figure 9b).  
Since CD95L mediated an elevation in the intracellular signal transduction molecule 
ceramide, and considering our observations of reduced [peroxide]cyt in Jurkat T-cells in 
response to synthetic ceramide, the effects of CD95L on [peroxide]cyt in Jurkat T-cells were 
consequently examined.  CD95L exposure of Jurkat T-cells mediated a decrease in DCF 
fluorescence.  ∆DCF MdX was significantly reduced after 2 hours treatment with 1µg/ml 
(p<0.01) and 8 hours following 500ng/ml CD95L (p<0.05; see Figure 9c), which was prior to 
any significant observations of apoptosis (p>0.05 for both concentrations; see Figure 9a) and 
after the accumulation of intracellular ceramide in response to either concentration of CD95L 
(see Figure 9b).  The reduction in ∆DCF MdX occurred with faster kinetics and was of 
greater magnitude following Jurkat T-cell treatment with 1µg/ml of CD95L than that 
observed following treatment with 500ng/ml CD95L.  The decrease in ∆DCF MdX following 
CD95L exposure reached a plateau after 4 and 8 hours treatment with 1µg/ml and 500ng/ml 
respectively (see Figure 9c). 
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Discussion. 
Controversially, it is reported here that the application of  short chain ceramides to T-
cells or monocytes induces a loss in cytosolic peroxide ([peroxide]cyt) levels. This is in 
contrast to the direct effects of synthetic short chain ceramides on the mitochondria that 
mediate an elevation in mitochondrial peroxide ([peroxide]m) production, as described 
previously by us [23] and by others [21, 22].  Collectively, this supports the notion that 
ceramide may differentially modulate the redox state at discrete sub-cellular compartments 
[35].  Indeed, several authors have recently suggested that ROS may inhibit caspase 3 
activity, where a reduction in ROS is associated with increased apoptosis [36,37]. Based on 
our evidence from antioxidant treatment of cells prior to ceramide addition which enhanced 
the apoptotic response, we hypothesise that in the cellular models utilised here, it is the 
reduction in [peroxide]cyt that is of primary importance in dictating the cellular response to 
ceramide rather than its mitochondrial effects. However, a mediator role for the loss of 
cytosolic peroxide cannot be clearly established from this data. 
 Jurkat T-cells exposed to synthetic, short chain ceramides show a time dependent 
elevation in the appearance of fragmented DNA, a marker for apoptosis, as described by 
others [2-3, 6-8, 12], which was maximal at 8 hours post-treatment with C2-ceramide 
(20µM).  We have previously reported no significant difference between the short chain C2- 
and C6- ceramides in the induction of apoptosis in T cells [23].  At 16 hours post-treatment, 
cell death induced by 20µM C2-ceramide was also associated with the formation of a sub-
population of Jurkat T-cells displaying a reduction in cell size coupled with the loss of 
membrane permeability evaluated by flow cytometric analysis of the cellular uptake of the 
membrane impermeable dye PI as the cells enter late apoptosis or secondary necrosis.  Unlike 
Jurkat T-cells, exposure of U937 cells to synthetic ceramide induced an accumulation of 
nucleoids in the G0/G1 phase of the cell cycle, which is indicative of cell cycle arrest [15-17] 
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but was not as pronounced as described previously [17].  The observation of growth arrest 
occurred after 16 hours incubation with 20µM C2-ceramide, later than the onset of apoptosis 
in Jurkat T-cells and was persistent for up to 36 hours.  Furthermore, cell size and membrane 
permeability remained unaltered by ceramide treatment, indicating no induction of necrosis.  
U937 monocytes are reported to undergo apoptosis upon exposure to concentrations of 
ceramide in excess of 20µM [12, 22].  
Contrary to the observation of ceramide mediated transient elevations in [peroxide]m 
[23], using the cytosolic peroxide sensitive dye DCFH-DA revealed an overall loss in 
[peroxide]cyt prior to the appearance of DNA fragmentation or G0/G1 growth arrest in Jurkat 
T-cells and U937 monocytes respectively.  An apoptotic response in Jurkat T-cells to C2-
ceramide was preceded by an immediate, almost exponential like reduction in [peroxide]cyt.  
In contrast, where growth arrest was observed in U937 monocytes, the decrease in 
[peroxide]cyt was initially delayed, and fell approximately 40 minutes post-treatment.  
Additionally, the maximal loss of [peroxide]cyt in U937 cells was smaller than that observed 
in Jurkat T-cells where it was associated with apoptosis.  The apparent loss of [peroxide]cyt 
was not due to the leakage of DCFH-DA from the cytosolic environment since cells remained 
viable as indicated by the minimal uptake of the membrane impermeable dye PI throughout 
the DCF analysis period.  Although 20µM C2-ceramide induced a population of Jurkat T-
cells with high PI uptake and reduced cell size after 16 hours treatment, these cells were 
excluded from [peroxide]cyt determination as they had undergone secondary necrosis.  Lower 
concentrations of synthetic ceramide (10µM), which did not compromise Jurkat T-cell 
membrane permeability following 16 hours treatment, showed reduced [peroxide]cyt which 
was not to a level that was associated with apoptosis.  The magnitude and kinetics of 
[peroxide]cyt loss may therefore be the true dictator of the cellular responses to synthetic 
ceramides.  
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In light of the evidence suggesting that cytoplasmic peroxide levels may play only a 
minor role in the oxidation of DCF [38,39], where the major catalysts are ferryl containing 
molecules, we believed it important to adopt a further analytical method that allows direct 
determination of ROS. Cytochrome c reduction by superoxide anion radical is widely used 
and accepted as a specific measure of oxidant formation, hence this methodology was 
adopted to substantiate our findings with DCF. Whilst no change in superoxide production in 
response to ceramide was recorded at 1 hour, both U937 cells and Jurkat T cells showed a 
lower capacity to reduce cytochrome at 16hrs, where the effect seen was greater in T-cells.  
The overall effects of NADPH oxidase inhibition with DPI and ceramide suggest that 
modulation of NADPH oxidase may be a contributor to the loss of [peroxide]cyt, observed, 
however, the data suggests that other unknown mechanisms may also contribute to this 
process. Furthermore, the correlation between DPI enhanced ceramide induced apoptosis at 
16 hours and loss of [peroxide]cyt provides further evidence for the hypothesis that loss of 
loss of [peroxide]cyt is the determining factor in cellular outcome.  Clearly more detailed 
examination of ceramide’s potential interaction with the NADPH oxidase system is required. 
If the excessive production of [peroxide]m were the sole mediator of apoptosis or 
growth arrest, then a beneficial effect might be expected by pre-treatment of Jurkat T-cells or 
U937 monocytes respectively with antioxidants.  However, we observed that the antioxidants 
NAC or GSH failed to abrogate synthetic ceramide mediated apoptosis at any time point. 
Furthermore, the inhibition of GSSG efflux (which was confirmed by demonstrating 
increased intracellular total GSH) with L-cystathionine or L-methionine did not protect Jurkat 
T-cells from C2-ceramide induced apoptosis despite offering protection against methotrexate 
(unpublished results) or puromycin [34] treatment. This again suggests that the effects of 
ceramide are not due to an increase in ROS. Surprisingly, in U937 monocytes NAC and GSH 
inhibited synthetic ceramide induced G0/G1 growth arrest by driving ceramide treated cells 
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into apoptosis as indicated by the presence of fragmented DNA.  In effect, antioxidants 
transformed the cellular response of U937 monocytes to ceramide exposure from a cytostatic 
to cytotoxic response.  Reducing the intracellular peroxide levels of U937 monocytes by pre-
treatment with antioxidants, which were not in themselves toxic, permits [peroxide]cyt to fall 
upon ceramide treatment to a level which confers apoptosis.  Whilst NAC and GSH treatment 
alone did cause a reduction in basal DCF fluorescence (-30a.u.), this was insufficient to 
induce apoptosis (where –55a.u. was associated with apoptosis in T cells), although higher 
concentrations of either antioxidant were toxic (data not shown). Indeed, several authors have 
recently suggested that ROS may inhibit caspase 3 activity, where a reduction in ROS below 
a minimum threshold is associated with increased apoptosis [36,37]. 
Mansat-de Mas et al., [12] observed elevated fluorescence of a DCFH-DA analogue, 
C2938, within 20 minutes treatment with C6-ceramide that returned to baseline after 30 
minutes, whereas Lee & Um, [25] described no alteration in DCF fluorescence following 
U937 exposure to C2-ceramide.  However, in our experiments the concentration of C2-/C6-
ceramide applied to whole cells encompasses the fluctuation range achieved by endogenous 
natural ceramides in response to external stimuli [reviewed in 40].  Where other authors have 
reported massive increases in ROS production at the mitochondria [22] the concentration of 
C2-/C6-ceramide used were in excess of 5 fold the concentration (per 106 cells) that we have 
used to elicit small transient increases in [peroxide]m [23] or the loss in [peroxide]cyt reported 
here.  The enhanced production of [peroxide]cyt described in response to high doses of 
ceramides/106 cells may therefore be a consequence of ROS leakage from the mitochondria 
into the cytosol with loss of compartmental redox effects.   
 The biochemical and molecular processes that lead to cellular responses to various 
agents analysed in immortalised cell lines are often criticised as they are continually cycling 
and possess higher metabolic rates.  It was therefore of importance to study the cellular and 
 25 
Phillips & Griffiths,  Ceramide reduces cytosolic peroxide. 
redox effects of synthetic short chain ceramides on normal, primary human cells.  The 
observation of reduced [peroxide]cyt precedes apoptosis in human CD3+ T-cells and CD14+ 
monocytes in peripheral whole blood treated with C2-/C6-ceramide and in purified resting T-
cells or PHA activated T-cells in vitro supports those data obtained from cell lines.  The 
ability of C2-ceramide to induce apoptosis which was preceded by loss in [peroxide]cyt, was 
independent of activation state and phase of the cell cycle, where identical levels of 
[peroxide]cyt loss and DNA fragmentation were observed in resting and PHA activated T-
cells.  Resting T-cells possessed only DNA that was in the G0 phase of the cell cycle whereas 
PHA activated T-cells displayed the appearance of a small number of S-phase and G2M 
phase nucleoids, indicating progression through the cell cycle.  In contrast, under identical 
culture conditions and treatments, Mengabas et al., [41] reported that C2-ceramide killed 
normal human T-lymphocytes via a non-apoptotic mechanism that was prevented by PHA 
activation.  In the data described herein, the membrane permeability of resting and activated 
primary human T-cells treated with C2-ceramide (0-20µM) was not compromised at 6 hours 
post-treatment when analysed for uptake of the membrane impermeable dye PI by flow 
cytometry indicating that necrosis did not contribute to the death process (Data not shown).   
In an attempt to analyse the effects of intrinsic endogenous ceramide generation on 
[peroxide]cyt, Jurkat T-cells were treated with the known inducer of ceramide accumulation, 
CD95L [6-8].  Herein, we have shown that Jurkat T-cell treatment with CD95L leads to an 
accumulation of ceramide within 30 minutes, which rose further at 1 hour.  This was 
followed by a reduction in [peroxide]cyt prior to the appearance of apoptosis.  Whilst the 
extent of apoptosis that we observed following treatment with 1µg/ml or 0.5µg/ml CD95L 
was similar to that mediated by 20µM C2-ceramide, the kinetics of the appearance of 
fragmented DNA were slower and correspondingly the magnitude reduction in [peroxide]cyt 
generation was less and occurred more slowly.  In contrast, others have shown that whilst 
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CD95 receptor stimulation induced ceramide formation in human glioma cells via the 
activation of A-SMase, no ROS formation was observed and the ensuing apoptosis 
unaffected by antioxidants [20].  Similarly, L929 cells expressing the CD95 receptor undergo 
CD95 induced apoptosis which is not inhibitable by antioxidants [42].  These observations 
are in contrast to the elevation in DCF fluorescence reported in IL-1β/TNFα activated 
peripheral blood monocytes [PBM] prior to apoptosis induced by CD95L exposure, both of 
which were inhibitable by antioxidants [43], and other studies which suggested that CD95 
induces ROS generation via stimulation of the NADPH oxidase system [44,45].  Others have 
also shown neuroglioma cells overexpressing Cu or ZnMnSOD showed marked attenuation 
of CD95 induced apoptosis, that catalase treatment inhibited CD95 induced apoptosis of 
normal neurogliomas [46], and that NAC or GSH inhibited CD95L induced apoptosis in 
HL60 variant HL-525, in the absence of an elevation in endogenous ceramides [47].  These 
discrepancies may exist due to differences in cell lineage or the degree of saturation and 
length of fatty acid chain between endogenous ceramides generated by ligands such as FAS 
and synthetic exogenously applied short chain ceramides.  However, during preparation of 
this manuscript, Aronis et al. have also published the observation of a decrease in ROS 
production in response to CD95 receptor stimulation in Jurkat T-cells that correlates with 
enhanced cell death [48], further supporting the impact of the observations reported here. 
We have observed that short chain ceramide manipulates the intracellular redox state 
through mitochondrial and non-mitochondrial pathways.  [peroxide]m generation may be 
important in parallel, but acting within a different sub-cellular compartment, to ceramide 
induced loss of [peroxide]cyt.  The loss of [peroxide]cyt in response to short chain ceramides in 
the immortalised cell lines of U937 monocytes and Jurkat T-cells has been reproduced in 
primary human cells of identical lineage, indicating that the effects are not related to cellular 
immortality.  Furthermore, the data presented here, taken together with our previous 
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observations [23] indicate the existence of discrete redox sensitive entities which may be 
targeted and manipulated by ceramide to produce independent responses.  
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Tables and Figures 
 
Figure 1.  Loss of endogenous, cytosolic peroxide from Jurkat T-cells precedes apoptosis.  
Jurkat T-cells (2x106/ml) were serum starved for 4 hours prior to the addition of C2-ceramide 
for 0-36 hours.  Incubations were performed at 37oC in a 95% air, 5% CO2 humidified 
atmosphere.  For DNA cell cycle analysis by flow cytometry (a), treatments were terminated 
by washing the cells twice with ice cold PBS, cell pellets resuspended in 1ml of hypotonic 
fluorochrome solution and incubated in the dark at 4oC overnight.  The sub-diploid DNA 
content of 20,000 nucleoids from each sample was analysed on a gated histogram of FL3 
(propidium iodide; PI) versus count.  The data are presented as the mean ± s.e.m of at least 7 
individual experiments, expressed as the percentage specific apoptosis according to the 
formula specific apoptosis = (T-C)/(100-C) x100, where T equals the percentage of apoptotic 
events from treated cells, and C equals the percentage of apoptotic events from control cells.  
For analysis of cytosolic peroxide levels (b), 40 minutes before termination of the incubation 
period, cell samples were loaded with 50µM DCFH-DA.  At the end of the treatment period, 
samples were analyses immediately for DCF fluorescence by flow cytometry as described in 
materials and methods and the median X (MdX) of 10,000 cells recorded.  Data is expressed 
as the mean ± s.e.m of at least 3 individual experiments. 
 
Figure 2.  C6-ceramide induced growth arrest in U937 monocytes is preceded by a loss in 
cytosolic peroxide.  U937 cells (2x106/ml) were serum starved in RPMI 1640 for 4 hours prior 
to the addition 0-20µM C6-ceramide and incubated in a humidified 5% CO2, 95% air atmosphere 
at 37oC for 8 - 36 hours.  For DNA cell cycle analysis by flow cytometry (a), treatments were 
terminated by washing the cells twice with ice cold PBS, cell pellets resuspended in 1ml of 
hypotonic fluorochrome solution and incubated in the dark at 4oC overnight.  The sub-diploid 
DNA content (% actual apoptosis) of 20,000 nucleoids from each sample was analysed on a 
gated histogram of FL3 (propidium iodide; PI) versus count.  The percentage G0/G1 content of 
DNA cell cycles were quantified using MultiCycleTM for Windows (Phoenix Flow Systems, San 
Diego, U.S.A.).  The data are presented as the arithmetic mean percents ± s.e.m of at least 3 
individual experiments.  * indicate p<0.05 or ** indicate p<0.01 compared to vehicle treatment 
by one way ANOVA followed by Dunnett’s multiple comparison test.  For analysis of cytosolic 
peroxide levels (b), U937 monocytes were treated as described in Figure 1.  Data is expressed as 
the mean ± s.e.m of at least 3 individual experiments. 
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Figure 3.  Ceramide-induced reduction of cytosolic peroxide is not directly related to 
NADPH oxidase inhibition of superoxide generation. U937 or Jurkat T cells (2x106/ml) were 
serum starved in RPMI 1640 for 4 hours with or without 10uM diphenylene iodinium (DPI) prior 
to the addition 20µM C2-ceramide for 16 hours at 37oC.  Prior to termination of the incubation 
period, cell samples were loaded with 50µM DCFH-DA for 40 minutes as described in Figure 1.  
Samples were analysed immediately for DCF fluorescence by flow cytometry and the median X 
(MdX) of 10,000 cells recorded (a & b).  The same samples were also analysed for evidence of 
apoptosis (c & d) by DNA cell cycle analysis as described in Figure 2.  U937 or Jurkat T cells 
(107/ml) were resuspended in phenol red free HBSS containing glucose with or without 10uM 
diphenylene iodinium (DPI) or 30U/ml superoxide dismutase (SOD) in the presence of 
cytochrome c (160µM) prior to the addition 20µM C2-ceramide for 16 hours at 37oC.  
Cytochrome c reduction was monitored at 550nm and the superoxide released calculated as 
described in the materials and methods (e & f).  All data are presented as the mean ± s.e.m of 3 
individual experiments and where * (p<0.05), ** (p<0.01) or *** (p<0.001) represents 
significant differences from vehicle treated control samples and + (p<0.05) or +++ (p<0.001) 
indicates significant difference from C2-ceramide treated cells. 
 
Figure 4.  Anti-oxidants drive synthetic ceramide treated U937 monocytes into apoptosis 
rather than growth arrest.  U937 cells (2x106/ml) were serum starved in RPMI 1640 for 4 
hours with or without 10mM N-acetylcysteine (NAC) or 10mM glutathione (GSH) prior to the 
addition 20µM C2-/C6-ceramide for 16 hours at 37oC.  Samples were prepared for DNA cell 
cycle analysis as described in Figure 2.  The sub-diploid DNA content recorded to represent 
the percentage actual apoptosis (a).  The percentage G0/G1 content of DNA (b) was quantified 
using MultiCycleTM for Windows (Phoenix Flow Systems, San Diego, U.S.A.). Data are 
presented as mean percentage ± s.e.m of 3 individual experiments.  * (p<0.05), ** (p<0.01) or 
*** (p<0.001) indicate significant difference of samples pre-treated with NAC or GSH 
compared to no pre-treatment by one way ANOVA followed by Tukey’s multiple comparison 
test.  For analysis of cytosolic peroxide (c), 50µM DCFH-DA was added to each sample 40 
minutes prior to the end of the incubation period.  At 16 hours, cell samples were analysed 
immediately for DCF fluorescence by flow cytometry as described in Figure 1.  Data are 
presented as mean percentages ± s.e.m (n=3).  ** (p<0.01) indicate significant difference 
between samples treated with 20µM C6-ceramide with GSH or NAC pre-treatment compared 
to no pre-treatment, xxx (p<0.001) represents significant difference of test samples from 
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control treated cells with no pre-treatment and ++ (p<0.01) indicates significant difference 
between test and control samples both pre-treated with NAC or GSH compared to one way 
ANOVA followed by Dunnett’s multiple comparison test. 
 
Figure 5.  Antioxidants do not protect Jurkat T-cells from ceramide mediated apoptosis.  
Jurkat T-cells (2x106/ml) were serum starved in RPMI 1640 for 4 hours with or without 10mM 
N-acetylcysteine (NAC) or 10mM glutathione (GSH) prior to the addition 20µM C2-ceramide 
for 1 to 12 hours (a).  Alternatively, cell suspensions were treated with 10mM L-cystathionine or 
L-methionine prior to treatment with 0-20µM C2-/C6-ceramide for 16 hours (b).  All incubations 
were performed in a humidified 5% CO2, 95% air atmosphere at 37oC for 36 hours.  Experiments 
were terminated by washing with ice cold PBS.  Cell pellets were resuspended in 1ml of 
hypotonic fluorochrome solution as described in materials and methods prior to DNA cell cycle 
analysis by flow cytometry.  20,000 nucleoids were counted per sample.  Data are presented as 
mean percentages ± s.e.m of between 3 and 7 individual experiments.  Data was analysed for 
significant difference between samples pre-treated with NAC, GSH, L-cystathionine or L-
methionine compared to no pre-treatment by one-way ANOVA followed by Tukey’s multiple 
comparison test.   
 
Figure 6.  Treatment of whole blood with C6-ceramide reduces the cytosolic peroxide 
concentration of CD3+ve T-lymphocytes and CD14+ monocytes.  Venous blood was 
obtained from healthy consenting adult humans and treated with 20µM C6-ceramide for 2 
hours at 37oC with rotation.  Reactions were terminated by incubation on ice with 
simultaneous treatment with the fluorescently tagged monoclonal antibodies CD3-PE and 
CD14-CY5PE, and 50µM DCFH-DA for 30 minutes.  Red blood cells were lysed and 
leukocytes fixed as described in methods.  Samples were analysed by flow cytometry and the 
DCF fluorescence of the CD3+ population and CD14+ population quantified.  Shown are 
typical flow cytometric histograms of (a) CD3-PE (FL2) versus SS, the highly fluorescent 
CD3+ cell population isolated and gated ‘Y’, (b) CD14-CY5PE (FL4) versus SS, the highly 
fluorescent CD14+ cell population isolated and gated ‘Z’, (c) DCF (FL1) versus count of the 
gated CD3+ population ‘Y’ and (e) DCF (FL1) versus count of the gated CD14+ population 
‘Z’.  Grey fill represent the DCF fluorescence of CD3+ (c) or CD14+ (d) populations 
respectively from vehicle treated whole blood, black outlines with no fill represent the DCF 
fluorescence obtained from whole blood treated with 20µM C6-ceramide.  Results are 
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representational of 3 independent experiments.  Histogram overlay was performed using 
WinMDI 2.8. 
 
Figure 7.  Synthetic short chain ceramides induce cytosolic peroxide loss in resting 
human T-lymphocytes prior to the appearance of DNA fragmentation.  Primary human 
peripheral blood T-lymphocytes were extracted by density centrifugation and purified by 
negative isolation.  T-cells were cultured for 3 days in RPMI 1640 (10% FCS, 1% P/S) at a 
concentration of 2x106/ml.  T-cells (1x106/ml) were then serum starved in RMPI 1640 for 4 
hours prior to exposure to C2-ceramide (0-20µM) for 6 hours (a & c) or 24 hours (b). For the 
quantification of apoptosis (a & b), samples were resuspended in hypotonic fluorochrome 
solution and incubated overnight in the dark at 4oC prior to DNA cell cycle analysis by flow 
cytometry as described in material and methods.  The percentage actual apoptosis was 
calculated from the sub-diploid content of 20,000 nucleoids per sample.  For analysis of 
cytosolic peroxide levels (c), 40 minutes before termination of incubation period, cell 
samples were loaded with 50µM of DCFH-DA.  At the end of the treatment period, samples 
were analysed immediately for DCF fluorescence by flow cytometry as described in materials 
and methods, and the median X (MdX) of 10,000 cells were recorded.  ∆DCF represents the 
change in DCF MdX of test samples from vehicle controls.  The data are presented as the 
arithmetic mean ± s.d of at least 3 individual experiments.  All cell culture and treatments 
were performed at 37oC in a humidified 95% air, 5% CO2 atmosphere.  Statistical analysis 
was performed by one way ANOVA followed by Dunnett’s post hoc test analysis, where ** 
(p<0.01) represents significant difference from controls.  Arbitrary units, a.u.  NS represents 
no significant difference between vehicle treated controls and tests. 
 
Figure 8.  Synthetic short chain ceramides induce cytosolic peroxide loss in activated 
human T-lymphocytes prior to the appearance of  DNA fragmentation.  Primary human 
peripheral blood T-lymphocytes were extracted by density centrifugation and purified by 
negative isolation (Dynal).  T-lymphocytes were cultured for 3 days in RPMI 1640 (10% 
FCS, 1% P/S) containing 10µg PHA per 2x106/ml T-cells.  T-cells were then serum starved 
in RMPI 1640 for 4hours prior to exposure to C2-ceramide (0-20µM) for 6 (a-e) or 24 hours 
(f—i).  For DNA cell cycle analysis by flow cytometry, samples were washed twice with ice 
cold PBS, resuspended in hypotonic fluorochrome solution and incubated overnight in the 
dark at 4oC.  The sub-diploid region of 20,000 nucleoids from each sample were evaluated on 
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gated histograms count versus FL3 (propidum iodide; PI).  Shown are DNA cell cycle 
histograms obtained from samples treated with vehicle (a & f), 5µM (b & g), 10µM (c & h) 
or 20µM (d & i) C2-ceramide.  Numbers represent the mean percentage of sub-diploid DNA 
± s.d of at least 3 individual experiments.  Data was analysed for statistical difference by one 
way ANOVA followed by Dunnett’s multiple comparison test where * (p<0.05) and ** 
(p<0.01) represents significant difference from controls.  For analysis of cytosolic peroxide 
levels (e), 40 minutes before termination of incubation period, cell samples were loaded with 
50µM of DCFH-DA.  At the end of the treatment period, samples were analysed immediately 
for DCF fluorescence by flow cytometry as described in materials and methods and the 
median X (MdX) of 10,000 cells were recorded.  Shown is an overlay of DCF histograms 
from T-cells treated with vehicle, 5µM, 10µM or 20µM C2-ceramide.  Histogram overlay was 
performed using WinMDI 2.8.  Results are representative of those obtained from at least 3 
individual experiments.  All cell culture and treatments were performed at 37oC in a 
humidified 5% CO2, 95% air atmosphere.   
 
Figure 9.  CD95 induced apoptosis in Jurkat T-cells is preceded by endogenous ceramide 
production and loss in cytosolic peroxide.  Jurkat T-cells (2x106/ml) were serum starved for 
4 hours prior to the addition of CD95 ligand (CD95L; 0-5µg/ml) for 0-24 hours.  Incubations 
were performed at 37oC in a 95% air, 5% CO2 humidified atmosphere and terminated by 
washing the cells twice with ice cold PBS prior to further experimental manipulation.  (a) For 
quantification of apoptosis, samples were prepared and analysed as described in Figure 1. (b) 
Lipids were extracted and endogenous ceramide quantified against a standard curve of known 
ceramide concentrations by the DAGK assay as described.  (c) For analysis of cytosolic 
peroxide levels, 40 minutes before termination of incubation period, cell samples were loaded 
with 50µM DCFH-DA.  At the end of the treatment period, samples were analysed 
immediately for DCF fluorescence by flow cytometry as described in materials and methods 
and the median X (MdX) of 10,000 cells were recorded.  ∆DCF MdX represents the difference 
in MdX DCF of CD95 treated cells from that of vehicle treated cells for each time point.  The 
data are presented as the mean ± s.e.m. of between 3 and 5 individual experiments, a.u. = 
arbitrary units. 
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